Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
82 hedge funds and large institutions have $476M invested in Adaptimmune Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 12 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 22
0% more call options, than puts
Call options by funds: $692K | Put options by funds: $691K
0.65% less ownership
Funds ownership: 12.62% → 11.97% (-0.65%)
2% less funds holding
Funds holding: 84 → 82 (-2)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
24% less capital invested
Capital invested by funds: $624M → $476M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.47M |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$3.03M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$2.76M |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$2.04M |
| 5 |
Goldman Sachs
New York
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$11.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.3M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$7.4M |
| 4 |
Millennium Management
New York
|
-$3.33M |
| 5 |
OAMG
Odey Asset Management Group
London,
United Kingdom
|
-$2.92M |
ADAP Hedge Fund Activity: Q2 2021 in Review
82 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2021, worth a combined $476M — down 24% from $624M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ADAP and 10 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 27 added.
The largest buyer was PFM Health Sciences, adding an estimated $5.47M. The largest seller was Morgan Stanley, cutting an estimated $11.8M.
- 82 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2021, down from 84 in Q1 2021.
- Funds reported $476M of Adaptimmune Therapeutics stock for Q2 2021, down 24% quarter-over-quarter.
- 10 funds opened new Adaptimmune Therapeutics positions in Q2 2021 and 12 closed out, a net change of -2 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2021 was PFM Health Sciences, an estimated $5.47M added.
- The largest Adaptimmune Therapeutics seller in Q2 2021 was Morgan Stanley, an estimated $11.8M sold.
Based on aggregated 13F filings for Q2 2021.